This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics. At enrollment, patients' clinical symptoms, laboratory findings, and chest imaging data will be collected. Longitudinal follow-up will be conducted to evaluate disease progression, complications, and long-term outcomes.
As an observational study, no interventions are involved; all patients receive routine clinical management as directed by their attending physicians. This real-world study design enables the assessment of the natural course of acute respiratory infections and the identification of factors associated with clinical outcomes.
Age ≥ 18 years (based on official identification document).
Presence of fever at the time of visit or within 24 hours prior to the visit, defined as a documented temperature of ≥37.3°C axillary/tympanic, ≥37.8°C orally, or ≥38.0°C rectally.
The primary cause of fever, as determined by the attending physician, is a respiratory tract infection.
Blood draw is required as part of standard clinical care.
Inability to provide independent informed consent due to impaired consciousness or other reasons.
Inability to comply with the study procedures.
Medical contraindications to blood sampling, such as severe coagulopathy (e.g., INR > 3.0, platelet count < 50 × 10⁹/L).
Diagnosed with a terminal illness (e.g., advanced malignancy, severe multiple organ failure) and a life expectancy of less than 3 months.
Patients presenting to fever clinics with acute respiratory infections, aged 18 years or older, who provide informed consent. Both sexes are eligible. Participants are observed under standard clinical care without intervention
Cohort
Prospective
No intervention involved
Other interventionThis is a observational study so no intervention involved.
Proportion of Participants Hospitalized for Pneumonia
The percentage of patients who require hospitalization due to radiologically confirmed pneumonia within the 30-day follow-up period.
Rate of Symptom Resolution at 24 Hours
Proportion of participants achieving complete resolution of patient-reported symptoms (e.g., fever, myalgia) at 24 hours after enrollment.
Rate of Symptom Resolution at 7 Days
Time to Sustained Symptom Resolution
All-cause Mortality Rate at 30 Days
Click on the lead sponsor to view all of their trials.
Fudan University
Lead sponsor
Huadong Hospital
Collaborator
